Endoscopic Application of Hemostatic Drug Powder in Lower Gastrointestinal Bleeding: A Pilot Study
Starting soon · Not applicable
Conditions studied: Bleeding After GI Endoscopy
In brief
This clinical trial will enroll patients at National Cheng Kung University Hospital. All patients who are hospitalized for lower gastrointestinal bleeding and undergo colonoscopy will be invited to participate. This study uses random allocation, with one Intervention group and one Standard group. Both groups will receive standard endoscopic hemostasis. Afterward, patients in the Intervention group will receive local administration of 1.5 g of tranexamic acid and 3 g of sucralfate. Following the endoscopic procedure, patients will be directly observed for 5 minutes to confirm successful hemostasis. All patients will be followed for 28 days to assess the occurrence of post-procedural rebleeding.
Key facts
- Study ID
- NCT07679139
- Run by
- National Cheng-Kung University Hospital
- People needed
- 60
- Starts
- 2026-07-01
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-07-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- patients suspect lower gastrointestinal bleeding
You may not qualify if…
- absence of indication for endoscopic hemostasis
- known allergy to sucralfate, TXA
- presence of a hollow organ perforation
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.